News headlines about Accuray (NASDAQ:ARAY) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Accuray earned a daily sentiment score of 0.10 on Accern’s scale. Accern also gave media stories about the medical equipment provider an impact score of 46.5406589419841 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media stories that may have effected Accern’s analysis:
- Accuray Gains on Radixact Unit, Solid Geographical Foothold (finance.yahoo.com)
- Cogentix Medical (CGNT) Looks Good: Stock Adds 13.3% in Session (finance.yahoo.com)
- Boston Scientific (BSX) vs. Accuray (ARAY) Financial Analysis (americanbankingnews.com)
- Accuray (ARAY) Cut to “Hold” at Zacks Investment Research (americanbankingnews.com)
A number of equities analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Accuray from a “buy” rating to a “hold” rating in a research report on Wednesday, March 7th. BidaskClub lowered shares of Accuray from a “buy” rating to a “hold” rating in a research report on Thursday, February 8th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company’s stock. Accuray presently has a consensus rating of “Hold” and an average price target of $7.21.
Accuray (NASDAQ:ARAY) last posted its quarterly earnings data on Tuesday, January 23rd. The medical equipment provider reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.05. Accuray had a negative net margin of 6.09% and a negative return on equity of 44.66%. The company had revenue of $100.33 million during the quarter, compared to analyst estimates of $90.31 million. During the same quarter last year, the firm posted ($0.11) EPS. The business’s revenue for the quarter was up 14.7% on a year-over-year basis. sell-side analysts expect that Accuray will post -0.19 earnings per share for the current year.
Accuray Company Profile
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.